OXBD

Oxford Biomedica plc

OXBDF.US oxb.com
6.15
+0.00 (+0.00%)
USD · PINK
52-week range
5.83
12.61
Trading at 5% of the 52-week range
Market Cap
705.69M
P/E Ratio
0.00
Forward P/E
2,000.00
Book Value
1.02
Div. Yield
N/A
% Institutions
63.55%
% Insiders
20.55%

1 Year

-19.8%

3 Year

+61.2%

10 Year

+194.7%
Description

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary "plug and play' dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

Company Information

Company Name
Oxford Biomedica plc
Sector
Healthcare
Industry
Biotechnology
Exchange
PINK
Currency: USD
Full Time Employees: 977
Phone: 44 1865 783 000
Website: oxb.com
Fiscal Year End: December
Description:

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary "plug and play' dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

Address:

Windrush Court, Oxford, United Kingdom, OX4 6LT

People

Directors & Officers

Name Title Year Born
Dr. Frank Mathias CEO & Director 1962
Dr. Lucinda Clair Crabtree Ph.D. CFO & Director 1979
Mr. Eric Schmidhäuser Chief Operating Officer NA
Ms. Sophia Bolhassan Head of Investor Relations NA
Ms. Natalie Louise Walter Chief Legal Officer & Company Secretary 1973
Ms. Lisa Doman Chief People Officer NA
Dr. Kyriacos Mitrophanous Ph.D. Chief Innovation Officer NA
Ms. Kati Hudson Head of Intellectual Property & Contracts NA
Mr. David M. Backer M.B.A. Durham Site Head NA
Dr. Sebastien Ribault Chief Business Officer NA

Financial Highlights

Market Cap: $705.69M
EBITDA: $-18.26M
Book Value: $1.02
Earnings/Share: $-0.36
Profit Margin: -17.85%
Operating Margin: -7.88%
ROA (TTM): -6.97%
ROE (TTM): -40.37%
Revenue (TTM): $168.74M
Revenue/Share (TTM): $1.51
Earnings Growth (YOY): 106.90%
Revenue Growth (YOY): 22.50%

Valuation Metrics

Enterprise Value: $797.23M
Trailing P/E: 0.00
Forward P/E: 2.00K

Shares Statistics

Shares Outstanding: 121.04M
Shares Float: 67.59M
% Insiders: 20.55%
% Institutions: 63.55%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$168.74M
Cost of Goods Sold
adjust
$-102.76M
Gross Profit
subtotal
$65.98M
SG&A
adjust
$-36.76M
R&D
adjust
$-5.06M
Other Operating Expense
adjust
$-159.88M
Operating Income
subtotal
$-32.96M
Other / Non-Operating Items
adjust
$2.83M
Net Income
subtotal
$-30.13M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about OXBDF.US!